Tyrosine kinase inhibitorFDA-approvedFirst-line
Tagrisso
Generic name: osimertinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
In clinical trials, osimertinib improved progression-free survival in patients with EGFR-mutated non-small cell lung cancer, with a median progression-free survival of approximately 10.1 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Researchers Find New Way to Rechallenge Cancer Drug After Severe Reaction | Lung Cancer | observational | — | Source → |
| Testing Treatments for EGFR-Mutated Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy for Advanced Lung Cancer: A Clinical Trial | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy for Advanced Lung Cancer After Osimertinib Failure | Lung Cancer | phase-3 | — | Source → |
| Osimertinib Linked to Rare but Fatal Lung Inflammation in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Combination Therapy Trial for Advanced Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Osimertinib for Lung Cancer with EGFR Mutation | Lung Cancer | phase-2 | — | Source → |
| Osimertinib Study for Early Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Durvalumab and Radiation Therapy in Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Advanced Lung Cancer Trial Investigates Tagrisso Treatment | Lung Cancer | preclinical | — | Source → |
| Osimertinib Resistance in Lung Cancer Linked to Altered Lipid Metabolism | Lung Cancer | lab-study | — | Source → |
| Study of BL-B01D1 and Osimertinib for Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Muscle Loss in Lung Cancer Patients on Osimertinib Treatment | Lung Cancer | observational | SMI loss was an independent predictor of shorter OS (median OS 25.5 vs. 29.8 months, aHR: 2.04 [95% CI, 1.02-4.09]; P = 0.045) | Source → |
| Osimertinib Maintains Quality of Life in Lung Cancer Patients | Lung Cancer | phase-3 | — | Source → |
| Testing Ivonescimab with Other Treatments for Non-Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Osimertinib Resistance in Lung Cancer Linked to Metabolic Regulation | Lung Cancer | lab-study | — | Source → |
| Testing a New Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Osimertinib, Surgery, and Radiation Therapy in Treating Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Osimertinib and Bevacizumab for EGFR Positive Non-Small Cell Lung Cancer with Brain Metastases | Lung Cancer | phase-2 | — | Source → |
| Osimertinib Efficacy in Lung Cancer Patients with EGFR Mutations | Lung Cancer | observational | The overall survival was significantly longer in the postoperative group than in the Stage IV group (median: 39.2 months and 28.5 months, respectively). | Source → |
| Evaluating Osimertinib with Chemotherapy for Non-small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing Cancer Treatment Models for Lung Cancer Patients | Lung Cancer | phase-3 | — | Source → |
| Durvalumab and Chemotherapy Tested in Lung Cancer Patients | Lung Cancer | phase-2 | Confirmed ORR was 16% (80% confidence interval: 7-30); response was maintained for more than 6 months in the four patients with confirmed response. | Source → |
| Sequential Afatinib and Osimertinib Therapy Shows Promise in Lung Cancer | Lung Cancer | observational | Sequential afatinib-osimertinib therapy achieved a median OS of 55 months compared to 32.3 months with alternative strategies. | Source → |
| Improving Osimertinib Resistance in Lung Cancer Cells | Lung Cancer | lab-study | — | Source → |
| Combining Osimertinib and Brain Radiation for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Combining Osimertinib with AKR1C3 Inhibitor May Help Overcome Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Combining two cancer drugs may improve lung cancer treatment | Lung Cancer | phase-3 | The combination nearly doubled progression-free survival (PFS) compared with chemotherapy (9.8 vs. 5.4 months; hazard ratio 0.34) | Source → |
| Osimertinib Linked to Increased Heart Risks | Lung Cancer | meta-analysis | — | Source → |
| Osimertinib with or without Chemotherapy in Lung Cancer Patients | Lung Cancer | phase-3 | Combining osimertinib with chemotherapy improved progression-free survival versus osimertinib alone (HR, 0.62; P < 0.001). | Source → |
| Osimertinib Resistance in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Cancer Cells May Use Special Structures to Resist Treatment | Lung Cancer | lab-study | — | Source → |
| Cost-effectiveness of Osimertinib for Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Osimertinib May Cause Heart Problems in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Osimertinib Effective for Lung Cancer Patients with EGFR Mutation | Lung Cancer | meta-analysis | Osimertinib demonstrated significantly superior objective response rate (ORR) compared to control treatments (relative risk [RR] = 1.59, 95% confidence interval [CI] = 1.16 to 2.17, p < .001), exceeding the minimal clinically important difference threshold. | Source → |
| Osimertinib and Chemotherapy Combination Shows Promise in Lung Cancer | Lung Cancer | phase-3 | The experimental group demonstrated longer median progression-free survival (15.7 vs 10.6 months) and overall survival (24.6 vs 17.5 months) compared to the control group. | Source → |
| Osimertinib Response Linked to Gene Mutation Frequency | Lung Cancer | observational | Patients with a variant allele frequency (VAF) ≥30% showed a mean overall survival of 31.4 months and a mean progression-free survival of 25.0 months. | Source → |
| Osimertinib Resistance in Lung Cancer: A New Signaling Pathway Identified | Lung Cancer | lab-study | — | Source → |
| Osimertinib May Help Some Lung Cancer Patients with Specific Mutation | Lung Cancer | observational | The patient achieved a progression-free survival of 10 months. | Source → |
| Rare Lung Cancer Mutation Responds to Afatinib and Osimertinib | Lung Cancer | observational | — | Source → |
| Researchers Explore Ways to Overcome Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| New Study Examines Osimertinib Effectiveness in Lung Cancer Patients | Lung Cancer | phase-2 | The objective response rate was 61.8%, and grade 3 or higher adverse events occurred in 22.1% of the patients. | Source → |
| Genetic Changes in Lung Cancer Patients Predict Treatment Outcomes | Lung Cancer | observational | Patients with mutations in exon 5 had a hazard ratio of 7.67 for reduced treatment period and 9.29 for overall survival compared to wild-type patients. | Source → |
| Eugenol May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| PD-L1 Expression May Affect Osimertinib Outcomes in Lung Cancer | Lung Cancer | meta-analysis | Higher PD-L1 expression (≥50%) was associated with a 3.03-fold increased risk of progression or death. | Source → |
| Researchers Find New Way to Overcome Osimertinib Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Monotherapy for Advanced Lung Cancer with Atypical EGFR Mutations | Lung Cancer | observational | Median progression-free survival was 8.8 months, and median overall survival was 28.5 months overall, 42.5 months in patients with compound EGFR mutations, and 20.0 months in those with atypical mutations alone. | Source → |
| Gene Amplification Linked to Osimertinib Efficacy in Lung Cancer | Lung Cancer | observational | Overall survival was significantly shorter for actinin-4 immunohistochemistry-positive patients than for actinin-4 immunohistochemistry-negative patients (hazard ratio, 2.76; 95% confidence interval, 1.02-7.45). | Source → |
| Understanding Drug-Tolerant Cancer Cells in Lung Cancer | Lung Cancer | lab-study | Notably, this strategy showed superior efficacy compared with osimertinib combinations with chemotherapy or AXL inhibitor in both settings. | Source → |
| PD-L1's Role in Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| New Cancer Compound Shows Promise in Lung Cancer Research | Lung Cancer | lab-study | Compound 14l achieved the lowest IC₅₀ values and strong EGFR kinase inhibition (IC₅₀ = 50.58 ± 3.87 nM). | Source → |
| New Compound May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Effective in Advanced Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 15.8 months, and the median overall survival was 29.3 months. | Source → |
| Osimertinib as First-Line Treatment for Lung Cancer | Lung Cancer | observational | The median first-line progression-free survival was 19.0 months in the osimertinib group. | Source → |
| PET Scans May Help Predict Lung Cancer Treatment Outcomes | Lung Cancer | observational | — | Source → |
| T cell immunity may slow down lung cancer resistance to treatment | Lung Cancer | observational | Patients with higher CXCR3CCR4CCR6CD4 T cell levels exhibited significantly enhanced PFS (p = 0.002) and OS (p = 0.0006). | Source → |
| New Study Compares Cancer Treatments for Lung Cancer Patients | Lung Cancer | meta-analysis | Osimertinib resulted in significantly longer overall survival compared to erlotinib-based regimens (HR for OS vs. erlotinib: 1.59, 95% CI 1.09-2.31). | Source → |
| Radiation Therapy Extends Time on Osimertinib for Some Lung Cancer Patients | Lung Cancer | observational | After XRT, time on osimertinib was extended for a median of 9.7 months, with a median progression-free survival (PFS) and overall survival of 6.9 and 24.4 months, respectively. | Source → |
| Osimertinib Effective in Treating Lung Cancer with Brain Metastases | Lung Cancer | observational | The CNS-ORR was 91.9% and the CNS-DCR was 100%. | Source → |
| Rare Side Effect of Osimertinib in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Understanding Resistance to Lung Cancer Drugs | Lung Cancer | lab-study | — | Source → |
| New Approach to Treating Lung Cancer Resistant to Osimertinib | Lung Cancer | lab-study | — | Source → |
| MDM2 protein linked to resistance to cancer treatment Osimertinib | Lung Cancer | lab-study | — | Source → |
| Comparing Treatments for Lung Cancer with EGFR Mutations | Lung Cancer | phase-3 | The median progression-free survival (PFS) did not differ significantly between 2 G EGFR-TKIs and osimertinib (del 19: 17.6 months; L858R: 20.0 months vs. 28.3 months, p = 0.081). | Source → |
| New Study Examines Treatment Options for Lung Cancer Patients | Lung Cancer | observational | The objective response rate was much higher in the immunotherapy + chemotherapy group compared with chemotherapy or osimertinib + bevacizumab group (55.56% vs. 14.81% vs. 0%). | Source → |
| Osimertinib Helps Patient with Lung Cancer | Lung Cancer | observational | — | Source → |
| Researchers Identify Resistance Mutations in Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Researchers Explore New Treatment for Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Osimertinib Efficacy and Safety in Advanced Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 20.0 months and the median overall survival was 41.0 months. | Source → |
| Ganoderma Protein May Help Fight Lung Cancer Cells Resistant to Osimertinib | Lung Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise for Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Osimertinib Shows Promise in Treating Rare Lung Cancer Mutations | Lung Cancer | phase-2 | — | Source → |
| Osimertinib as Neoadjuvant Therapy for Lung Cancer | Lung Cancer | phase-2 | The major pathological response rate was 14.8% (95% CI, 4.2 to 33.7). | Source → |
| Targeted therapy shrinks lung lesions and improves bone metastases in lung cancer patient | Lung Cancer | observational | — | Source → |
| Cancer Cells Adapt to Treatment with EGFR Inhibitors | Lung Cancer | lab-study | Combining osimertinib with elesclomol significantly increases the efficacy of osimertinib, with no additional toxicity. | Source → |
| Rare Lung Cancer Mutation Responds to Osimertinib | Lung Cancer | observational | — | Source → |
| Predicting Osimertinib Effectiveness in Brain Cancer | Lung Cancer | lab-study | The radiomic model showed an area under the receiver operating characteristic curve (AUC) of 0.786 for the validation cohort. | Source → |
| Osimertinib Effective in Rare Lung Cancer Cases | Lung Cancer | phase-2 | The overall response rate was 55.0%. | Source → |
| Reduced Dosing of Osimertinib May Be a Treatment Option for Lung Cancer | Lung Cancer | observational | The objective response rate was 31.8%, and the disease control rate was 72.7%. | Source → |
| Osimertinib May Be a Viable Second-Line Treatment for Lung Cancer | Lung Cancer | observational | The best tumor response rate was 42.7%, with a median time on treatment of 5.6 months. | Source → |
| Rare Blood Disorder Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Combining Radiation and Osimertinib Treatments for Lung Cancer | Lung Cancer | meta-analysis | Osimertinib and similar third-generation EGFR-TKIs performed better in the brain, helping patients with central nervous system (CNS) responses of 60% to 91%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.